FDA agrees to consider approval of new anticoagulant from Merck

07/24/2013 | American City Business Journals

The FDA has accepted Merck's application for approval for its blood clot drug vorapaxar. The anticoagulant medication is meant to prevent stroke and myocardial infarction in patients who have experienced MI but not stroke. The therapy had been seen as a possible blockbuster, but safety concerns led Merck to narrow the indications.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC